JENCYCLA
Clinical safety rating
cautionComprehensive clinical and safety monograph for JENCYCLA (JENCYCLA).
JENCYCLA (sodium phenylbutyrate and ursodoxicoltaurine) is a fixed-dose combination. Sodium phenylbutyrate is a nitrogen-binding agent that conjugates with glutamine to form phenylacetylglutamine, which is excreted renally, reducing ammonia levels. Ursodoxicoltaurine is a hydrophilic bile acid that replaces toxic bile salts, reduces hepatocyte apoptosis, and improves bile flow.
| Metabolism | Sodium phenylbutyrate is metabolized via beta-oxidation to phenylacetate, which conjugates with glutamine. Ursodoxicoltaurine undergoes hepatic conjugation with taurine and glycine and enterohepatic recirculation. |
| Excretion | Renal: 35-45% unchanged; biliary/fecal: 50-60% as metabolites |
| Half-life | 8-12 hours; prolonged to 24 hours in severe hepatic impairment |
| Protein binding | 92-96% bound to albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | 3.5-5.0 L/kg; indicates extensive tissue distribution |
| Bioavailability | Oral: 75-90%; IV: 100% |
| Onset of Action | Oral: 1-2 hours; IV: 5-10 minutes |
| Duration of Action | 6-8 hours; extended in renal impairment |
| Molecular Weight | 280.32 |
1-2 mg/kg IV once daily every 3-4 weeks; maximum dose 100 mg.
| Dosage form | TABLET |
| Renal impairment | GFR 30-50 mL/min: reduce dose by 50%. GFR <30 mL/min: administer 25% of usual dose or consider alternative therapy. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: contraindicated. |
| Pediatric use | 0.5-1 mg/kg IV every 3-4 weeks; not established for weight <10 kg. |
| Geriatric use | No specific dose adjustment; monitor renal function and consider starting at lower end of dosing range due to age-related decline in renal function. |
| 1st trimester | Contraindicated due to risk of congenital malformations (neural tube defects, oral clefts). |
| 2nd trimester | Contraindicated due to risk of fetal toxicity and renal impairment. |
| 3rd trimester | Contraindicated due to risk of premature closure of ductus arteriosus and oligohydramnios. |
Clinical note
Comprehensive clinical and safety monograph for JENCYCLA (JENCYCLA).
| Placental transfer | Extensively crosses the placenta; achieves fetal concentrations approximately 50% of maternal levels. |
| Breastfeeding | Excreted into breast milk; potential for serious adverse reactions in nursing infants, including gastrointestinal bleeding and renal impairment. Use is not recommended. |
| Lactation Rating | L5 - Contraindicated |
| Teratogenic Risk | JENCYCLA (asciminib) is not recommended during pregnancy. Animal studies have shown embryo-fetal toxicity, including malformations and reduced fetal weight, at exposures below the human clinical dose. There are no adequate human studies. Use effective contraception during treatment and for at least 1 week after the last dose. First trimester: Potential for major congenital anomalies. Second and third trimesters: Risk of fetal growth restriction and adverse effects on fetal development. |
| Fetal Monitoring | Monitor maternal complete blood count, hepatic function, pancreatic enzymes (amylase/lipase), and blood pressure regularly. Assess for signs of pancreatitis, hepatotoxicity, and hypertension. Fetal monitoring via ultrasound for growth and development if exposure occurs. |
| Fertility Effects | JENCYCLA may impair fertility in males based on animal studies showing reduced sperm count and motility at clinically relevant exposures. Reversible after discontinuation. Effects on female fertility unknown; advise women of childbearing potential to use effective contraception. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to diclofenac or any excipientHistory of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDsActive peptic ulcer or gastrointestinal bleedingSevere heart failure (NYHA Class III-IV)Severe hepatic impairment (Child-Pugh Class C)Severe renal impairment (eGFR <30 mL/min/1.73 m²)Third trimester of pregnancyCoronary artery bypass graft (CABG) surgery perioperatively
| Precautions | Neurotoxicity due to phenylacetate accumulation (monitor neurologic status); pancreatic insufficiency; hyperammonemic encephalopathy; fluid overload; electrolyte disturbances; hepatotoxicity; hypersensitivity reactions; gastrointestinal disorders. |
| Food/Dietary | Avoid grapefruit and grapefruit juice as they may increase estrogen levels and risk of side effects. No specific food restrictions; however, high-fat meals may increase absorption variability. Consistent intake with or without food is recommended. |
| Clinical Pearls | JENCYCLA (norethindrone/ethinyl estradiol) is a combined oral contraceptive; counsel patients to take at the same time daily to maintain consistent hormone levels and maximize efficacy. Advise use of backup contraception during the first 7 days of therapy. Be aware of increased risk of venous thromboembolism, especially in smokers over 35 years of age. Monitor for breakthrough bleeding; if it persists beyond 3 cycles, consider alternative formulation. |
| Patient Advice | Take one tablet daily at the same time, preferably with food to reduce nausea. · If you miss a dose, refer to the package insert instructions; consider backup contraception if needed. · Common side effects include nausea, breast tenderness, and spotting; these often improve within a few cycles. · Seek immediate medical attention for leg pain/swelling, chest pain, shortness of breath, or severe headache. · Do not smoke while taking this medication, especially if over 35 years old. · This medication does not protect against sexually transmitted infections (STIs). |
Loading safety data…